Triple-Negative Breast Cancer (TNBC) is one of the most aggressive and heterogeneous subtypes of breast cancer, characterized by poor prognosis and often develops resistance to conventional therapy. The current study employs an integrative in silico approach to identify and evaluate the potential of phytocompounds to target genes or proteins associated with drug resistance in TNBC. This work uses high-throughput sequencing expression profiling datasets from the NCBI Gene Expression Omnibus (GEO) database to identify differentially expressed genes. Protein-protein interaction network analyses were employed further to understand the interconnectivity of these genes, ultimately narrowing down potential druggable targets (CDK1, MAOA, DHFR, TYMS). Selected phytochemicals were screened against identified target proteins using pharmacokinetic profiling (ADMET) and molecular docking. Our findings suggest that kirenol, artesunate, apigenin, daidzein, and sclareol have the potential to target specific genes involved in chemoresistance in TNBC and can serve as therapeutic options against drug-resistant TNBC.
Ritu Raj, S. Dang, R. Gabrani· Medicinal Plants - Internati...· 0 citations
Neuropsychiatric disorders are one of the major neurodegenerative disorders that affect
people. These disorders could be treated effectively by targeting drugs to the brain and overcoming
the blood-brain barrier (BBB). Nanotechnology has proven its worth in targeting and delivering drug
molecules to the target site. Various nanocarrier formulations have been utilized tremendously to
target drugs to the brain via the intranasal pathway and have shown significant results in treating the
disorders, since this pathway has emerged as a promising non–invasive alternative way of directly
offering the drug to the brain via the olfactory and trigeminal pathway, which also bypasses systemic
circulation and the hepatic first- pass effects. Nanotherapeutic approaches enhance the bioavailability,
biodegradability, and protection of drug molecules from enzymatic degradation in nanoformulations;
that is, they prevent enzymatic degradation of the drug. Moreover, these nanostructures have
customizable surface properties that enable controlled drug release, thereby increasing targeting efficiency
and leading to sustained therapeutic action. The current review focuses on the intranasal route
of administration and shows nano formulations are effectively delivered to the brain via this route.
This review provides readers with an insight into how different nano-carrier-based formulations,
such as polymeric-based nanoparticles, nano-lipid carriers, nano-emulsions, and solid lipid nanocarriers,
enhance drug bioavailability, target affinity, and overcome first-pass metabolism, and also
highlights the recent advancements and formulation approaches to optimize drug targeting to the
brain in order to manage complex neurological disorders.
Nikita Arora, S. Dang· Current Nanomaterials· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
